Neo­vacs signs €65M Chi­na deal; An­oth­er biotech CEO chat­ters on about a pos­si­ble buy­out

• Paris-based Neo­vacs says it signed up BioSense Glob­al for a €65 mil­lion deal cov­er­ing the de­vel­op­ment of its IFNα Ki­noid vac­cine to treat …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.